Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 32,876	$ 32,340
Cost of sales	(11,682)
Gross profit	21,194	32,340
Research and development expenses	(446,384)	(502,935)
Selling and marketing expenses	(27,199)	(26,669)
General and administrative expenses	(955,131)	(1,984,458)
Operating loss	(1,407,520)	(2,481,722)
Financing income, net	109	4,887
Loss before equity in net loss of equity investments	(1,407,411)	(2,476,835)
Less: Equity in net loss of equity investments		(477)
Net loss	(1,407,411)	(2,477,312)
Net loss attributable to non-controlling interests	24,234	13,012
Net loss attributable to the Company’s stockholders	$ (1,383,177)	$ (2,464,300)
Diluted net loss per share	$ (0.00)	$ (0.00)
Net loss per share - Diluted	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding used in computing basic net loss per share	522,762,226,201	516,812,963,552
Weighted average number of shares outstanding used in computing diluted net loss per share	522,762,226,201	516,812,963,552
Comprehensive loss:
Other comprehensive loss - Foreign currency translation adjustments	$ (1,121)	$ (2,273)
Comprehensive loss	(1,408,532)	(2,479,585)
Net - loss attributable to equity investments	24,234	13,012
Other comprehensive loss attributable to non-controlling interests	(1,077)	(1,216)
Comprehensive loss attributable to the Company’s stockholders	$ (1,385,375)	$ (2,467,789)